BioCentury
ARTICLE | Company News

Dainippon Sumitomo, Shionogi sales and marketing update

June 11, 2012 7:00 AM UTC

Dainippon and Shionogi partnered to co-market Dainippon's amlodipine besylate/irbesartan ( DSP-8153) in Japan. The product is an oral combination of amlodipine besylate, a calcium channel blocker, and irbesartan, an angiotensin II type 1 (AT1) receptor (AGTR1) antagonist. Last November, Dainippon submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for the product to treat hypertension. Details were not disclosed (see BioCentury, Dec. 5, 2011). ...